Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
HIMS Soars
Description
Hims & Hers Health shares rose 9.63% premarket after backing FDA plans to ease peptide therapy restrictions. Health Secretary RFK Jr. said the FDA will review select peptides in July with potential removal from the high-risk list. The company sees new revenue opportunities in regulated peptide channels. BofA cut its price target to $21, citing 2026 EBITDA pressure as GLP-1 contribution declines.
More from User
00:58
Nvidia's Robust Chip Growth
Benzinga
01:15
BYD Breaks Sales Slump
Benzinga
01:04
PM Cuts Outlook
Benzinga
00:58
Florida Sues OpenAI
Benzinga
00:53
SpaceX Eyes FCC Rule
Benzinga
00:54
Nvidida Eyes AI PCs
Benzinga
Related Videos
04:15
Novo Nordisk reports Q1 profits o $3.65 BN as demand for weightloss drug soars
CGTN Europe
01:39:48
Hate Him, Yet My Heart Beats Only For Hims
Rough.Render
05:42
EUA ng Pfizer vaccines para sa mga edad 5-11, aprubado na ng FDA; Pilipinas, tumaas ang puwesto sa COVID-19 response ranking ng Bloomberg
PTVPhilippines
00:30
But de Hims - Team A
LE FIVE 4PADEL
00:08
Meet Milo! Hims here to just make your weekend better!
Britneymurphy
20:17
Hims and Hers CEO on Growth Beyond Sex Medication
Bullish Studio